文献速递肝病

索磷布韦、维帕他韦和伏西拉韦治疗慢性HCV感染8周的疗效:2项3期随机试验

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
PubMed 文献 · Gastroenterology · 2017-04-05

在2项3期开放标签试验中,既往未接受直接抗病毒药物治疗的慢性HCV感染者随机接受索磷布韦-维帕他韦-伏西拉韦8周或索磷布韦-维帕他韦12周。POLARIS-2未达到8周方案对12周方案的非劣效性(SVR 95% vs 98%,差异-3.2%,95%CI -6.0%至-0.4%);POLARIS-3中基因3型合并肝硬化患者两方案SVR均为96%,显著优于83%的性能目标。

要点

  • POLARIS-2中8周索磷布韦-维帕他韦-伏西拉韦的SVR为95%,未达到对12周索磷布韦-维帕他韦(98%)的非劣效性。
  • POLARIS-3中基因3型合并肝硬化患者两方案SVR均为96%,显著优于83%的性能目标。
  • 含伏西拉韦方案中腹泻和恶心报告更频繁,因不良事件停药比例低(范围0%-1%)。

核心结论

  • 在3期试验中,未确立索磷布韦-维帕他韦-伏西拉韦8周对索磷布韦-维帕他韦12周的非劣效性,但两方案在HCV基因3型合并肝硬化患者中SVR率相似。
  • 含伏西拉韦的治疗方案与轻度胃肠道不良事件相关。

研究设计与样本

  • 2项3期开放标签随机试验,纳入既往未接受直接抗病毒药物治疗的HCV感染患者,随机分配至索磷布韦-维帕他韦-伏西拉韦8周组或索磷布韦-维帕他韦12周组。
  • POLARIS-2纳入所有HCV基因型(除基因3型合并肝硬化)伴或不伴肝硬化患者,以5%为非劣效界值检验8周方案对12周方案的非劣效性。
  • POLARIS-3纳入HCV基因3型合并肝硬化患者,以83%为性能目标比较两组SVR率。

主要发现

  • POLARIS-2中,8周索磷布韦-维帕他韦-伏西拉韦组SVR为95%(95%CI 93%-97%),12周索磷布韦-维帕他韦组SVR为98%(95%CI 96%-99%),分层调整的Mantel-Haenszel比例差异为-3.2%(95%CI -6.0%至-0.4%),未达到非劣效性标准。
  • 疗效差异主要由于接受8周索磷布韦-维帕他韦-伏西拉韦的HCV基因1a型感染患者SVR率较低(92%)。
  • POLARIS-3中,两治疗组SVR均为96%(95%CI 91%-99%),显著优于性能目标。
  • 总体最常见不良事件为头痛、乏力、腹泻和恶心;接受伏西拉韦的患者报告腹泻和恶心更频繁。
  • 两项试验中因不良事件停药的患者比例低(范围0%-1%)。

关键数值与推荐

  • POLARIS-2非劣效界值为5%。
  • POLARIS-3性能目标为83%。
  • POLARIS-2中8周组SVR 95%(95%CI 93%-97%)vs 12周组98%(95%CI 96%-99%),差异-3.2%(95%CI -6.0%至-0.4%)。
  • POLARIS-3中两治疗组SVR均为96%(95%CI 91%-99%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Patients with chronic hepatitis C virus (HCV) infection have high rates of sustained virologic response (SVR) after 12 weeks of treatment with the nucleotide polymerase inhibitor sofosbuvir combined with the NS5A inhibitor velpatasvir. We assessed the efficacy of 8 weeks of treatment with sofosbuvir and velpatasvir plus the pangenotypic NS3/4A protease inhibitor voxilaprevir (sofosbuvir-velpatasvir-voxilaprevir). METHODS: In 2 phase 3, open-label trials, patients with HCV infection who had not been treated previously with a direct-acting antiviral agent were assigned randomly to groups given sofosbuvir-velpatasvir-voxilaprevir for 8 weeks or sofosbuvir-velpatasvir for 12 weeks. POLARIS-2, which enrolled patients infected with all HCV genotypes with or without cirrhosis, except patients with genotype 3 and cirrhosis, was designed to test the noninferiority of 8 weeks of sofosbuvir-velpatasvir-voxilaprevir to 12 weeks of sofosbuvir-velpatasvir using a noninferiority margin of 5%. POLARIS-3, which enrolled patients infected with HCV genotype 3 who had cirrhosis, compared rates of SVR in both groups with a performance goal of 83%. RESULTS: In POLARIS-2, 95% (95% confidence interval [CI], 93%-97%) of patients had an SVR to 8 weeks of sofosbuvir-velpatasvir-voxilaprevir; this did not meet the criterion to establish noninferiority to 12 weeks of sofosbuvir-velpatasvir, which produced an SVR in 98% of patients (95% CI, 96%-99%; difference in the stratum-adjusted Mantel-Haenszel proportions of -3.2%; 95% CI, -6.0% to -0.4%). The difference in the efficacy was owing primarily to a lower rate of SVR (92%) among patients with HCV genotype 1a infection receiving 8 weeks of sofosbuvir-velpatasvir-voxilaprevir. In POLARIS-3, 96% of patients (95% CI, 91%-99%) achieved an SVR in both treatment groups, which was significantly superior to the performance goal. Overall, the most common adverse events were headache, fatigue, diarrhea, and nausea; diarrhea and nausea were reported more frequently by patients receiving voxilaprevir. In both trials, the proportion of patients who discontinued treatment because of adverse events was low (range, 0%-1%). CONCLUSIONS: In phase 3 trials of patients with HCV infection, we did not establish that sofosbuvir-velpatasvir-voxilaprevir for 8 weeks was noninferior to sofosbuvir-velpatasvir for 12 weeks, but the 2 regimens had similar rates of SVR in patients with HCV genotype 3 and cirrhosis. Mild gastrointestinal adverse events were associated with treatment regimens that included voxilaprevir. ClinicalTrials.gov numbers: POLARIS-2, NCT02607800; and POLARIS-3, NCT02639338.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Jacobson IM, Lawitz E, Gane EJ, et al. Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. Gastroenterology. 2017. PMID: 28390869. doi:10.1053/j.gastro.2017.03.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。